Site Editor
Thomas Flaig, MD
Thomas Flaig, MD
Posted: Friday, June 23, 2023
Consistent with prior analyses, data from the IMvigor130 trial, which were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 4503), indicate that patients treated with cisplatin-based chemotherapy may benefit more from the addition of the PD-L1 inhibitor atezolizumab than those treated with carboplatin-based chemotherapy. In addition, “in this post hoc analysis, the initial response to induction therapy did not seem to impact overall survival outcomes,” explained Enrique Grande, MD, PhD, MSc, of MD Anderson Cancer Center, Madrid, and colleagues.
This continued analysis of the IMvigor130 trial compared patients with metastatic urothelial carcinoma treated with gemcitabine and cisplatin to patients treated with gemcitabine and carboplatin. To begin the next phase, patients were required to lack evidence of progressive disease after four to six cycles of treatment. At this point, they were randomly assigned to receive induction immunotherapy with atezolizumab or a placebo. A post hoc analysis was performed on those who tolerated at least one dose of induction immunotherapy and had evidence of stable disease to assess the impact of therapy on overall survival.
The study findings revealed improvements in overall survival for those receiving combination therapy with atezolizumab, gemcitabine, and cisplatin (28.4 months) compared with carboplatin (18.5 months). In addition, the comparison of patients with stable disease receiving combination therapy with gemcitabine and cisplatin with and without atezolizumab showed overall survival rates of 47% and 34%, respectively, suggesting the added benefit of atezolizumab immunotherapy in this patient population.
Disclosure: For full disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
